Company: LENZ
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0001193125-25-100630
Chunk: 82

Company: LENZ Therapeutics, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 82
---
. |

| (17) | Consists of (i) 777,319 shares of Common Stock beneficially owned by our executive officers and directors, (ii) 1,127,315 shares of Common Stock subject to options held our executive officers and directors and exercisable within 60 days of April 14, 2025, and (iii) 6,575 shares of Common Stock subject to warrants beneficially owned by our executive officers and directors. |

Please see the sections titled “ Executive Compensation” and “ Related Person Transactions” appearing elsewhere in this proxy statement for information regarding material relationships with our principal securityholders within the past two years. -43-

RELATED PERSON TRANSACTIONS Described below are any transactions occurring since January 1, 2023 and any currently proposed transactions to which we or either of Graphite or LENZ OpCo was a party and in which:

| • |     | the amounts involved exceeded or will exceed the lesser of $120,000 or 1% of the average of our, Graphite or LENZ OpCo’s total assets, as applicable, at year-end for the last two completed fiscal years; and |

| • |     | a director, executive officer, holder of more than 5% of the outstanding capital stock of us, Graphite or LENZ OpCo, or any member of such person’s immediate family had or will have a direct or indirect material interest. |

Certain Relationships and Related Person Transactions—Graphite License and Option to Acquire Nula-CelAssets On August 4, 2023, Graphite entered into a license and option agreement (“LOA”) with Kamau Therapeutics, Inc. (“Kamau”) pursuant to which it exclusively licensed to Kamau, and granted Kamau, an option to acquire certain intellectual property and materials related to its nula-celprogram and related pre-clinicalplatform assets. The option included rights to assume the exclusive license agreement and the option agreement with The Board of Trustees of the Leland Stanford Junior University, as well as the license agreement with Integrated DNA Technologies, Inc., among other agreements. Exercise of the option was contingent on Kamau raising a minimum of $10 million in funds no later than August 4, 2024 (the “Financing Milestone”), which contingency could be waived by Graphite. In return for this license and option, Graphite received an equity interest in Kamau representing 20% of all outstanding shares on a fully diluted basis subject to dilution protection until